Clinical Trials Directory

Trials / Conditions / Extranodal NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma

25 registered clinical trials studyying Extranodal NK/T-cell Lymphoma — 7 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingStudy of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
NCT05700448
CStone PharmaceuticalsPhase 3
RecruitingCombination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in
NCT07525466
Beijing Tongren HospitalPhase 1 / Phase 2
Not Yet RecruitingTislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
NCT07502768
Rong TaoPhase 1 / Phase 2
Not Yet RecruitingGolidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly
NCT07385989
WEI XUPhase 2
RecruitingSintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
NCT06824883
Peking Union Medical College HospitalPhase 2
Active Not RecruitingDose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-
NCT05377827
Washington University School of MedicinePhase 1
RecruitingClinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
NCT05941156
The Affiliated Hospital of Xuzhou Medical UniversityPhase 2
UnknownThe Whole-course Management of Pegaspargase in ENKTL
NCT05426824
The First Affiliated Hospital with Nanjing Medical UniversityN/A
Active Not RecruitingPhase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
NCT04526834
Tessa TherapeuticsPhase 1
Active Not RecruitingA Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
NCT04414163
ImmuneOncia Therapeutics Inc.Phase 2
UnknownPrognostic Nomogram of Extranodal NK/T-cell Lymphoma
NCT04554511
Sun Yat-sen University—
UnknownCombination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
NCT04337593
Beijing Tongren HospitalPhase 2
UnknownSintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
NCT04279379
Beijing Tongren HospitalPhase 2
UnknownGPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
NCT04917250
Beijing Tongren HospitalPhase 2
UnknownVT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients
NCT03671850
ViGenCell Inc.Phase 2
CompletedB-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma
NCT03246750
The Thai Lymphoma Study GroupPhase 1 / Phase 2
UnknownTofacitinib Combined With Chidamide in R/R ENKTCL
NCT03598959
Sichuan UniversityPhase 2
CompletedStudy of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451
BeiGenePhase 2
RecruitingSafety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL
NCT06406556
Sun Yat-sen UniversityPhase 2
UnknownVP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cel
NCT02544425
Samsung Medical CenterPhase 2
TerminatedBortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma
NCT02808091
National Cancer Centre, SingaporePhase 2
CompletedRetrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma
NCT01341119
Samsung Medical Center—
UnknownImmunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
NCT00725231
University of GöttingenPhase 3
No Longer AvailableAn Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natur
NCT05131438
EQRx International, Inc.—